DK0470128T4 - Aktive polyalkylenoxidcarbonater til modifikation af polypeptider - Google Patents

Aktive polyalkylenoxidcarbonater til modifikation af polypeptider

Info

Publication number
DK0470128T4
DK0470128T4 DK90906698T DK90906698T DK0470128T4 DK 0470128 T4 DK0470128 T4 DK 0470128T4 DK 90906698 T DK90906698 T DK 90906698T DK 90906698 T DK90906698 T DK 90906698T DK 0470128 T4 DK0470128 T4 DK 0470128T4
Authority
DK
Denmark
Prior art keywords
polypeptides
modification
polyalkylene oxide
peg
oxide carbonates
Prior art date
Application number
DK90906698T
Other languages
English (en)
Other versions
DK0470128T3 (da
Inventor
Shmuel Zalipsky
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23335516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0470128(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzon Inc filed Critical Enzon Inc
Publication of DK0470128T3 publication Critical patent/DK0470128T3/da
Application granted granted Critical
Publication of DK0470128T4 publication Critical patent/DK0470128T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
DK90906698T 1989-04-19 1990-04-19 Aktive polyalkylenoxidcarbonater til modifikation af polypeptider DK0470128T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34092889A 1989-04-19 1989-04-19
PCT/US1990/002133 WO1990013540A1 (en) 1989-04-19 1990-04-19 Active carbonates of polyalkylene oxides for modification of polypeptides

Publications (2)

Publication Number Publication Date
DK0470128T3 DK0470128T3 (da) 2000-01-10
DK0470128T4 true DK0470128T4 (da) 2003-12-01

Family

ID=23335516

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98203166T DK0893439T3 (da) 1989-04-19 1990-04-19 Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid
DK90906698T DK0470128T4 (da) 1989-04-19 1990-04-19 Aktive polyalkylenoxidcarbonater til modifikation af polypeptider

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98203166T DK0893439T3 (da) 1989-04-19 1990-04-19 Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid

Country Status (10)

Country Link
EP (2) EP0470128B2 (da)
JP (1) JP2875884B2 (da)
AT (2) ATE300519T1 (da)
AU (1) AU5526690A (da)
CA (1) CA2053317C (da)
DE (2) DE69033192T3 (da)
DK (2) DK0893439T3 (da)
ES (2) ES2247656T3 (da)
HU (1) HUT64022A (da)
WO (1) WO1990013540A1 (da)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5583114A (en) * 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
AU5893696A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
CZ20022727A3 (cs) 2000-01-10 2002-11-13 Maxygen Holdings Ltd Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek
CN100488562C (zh) 2000-02-11 2009-05-20 拜耳医药保健有限公司 凝血因子VⅡ或VⅡa样分子
AU2001238384B2 (en) 2000-02-17 2006-05-18 Neomend, Inc. Delivery systems using preformed biodegradable polymer compositions and methods
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
BR0207576A (pt) 2001-02-27 2004-04-27 Maxygen Aps Variante glicosilada de um polipeptìdeo de interferon beta precursor (ifnb), processos de aumentar a glicosilação in vivo de uma molécula de ifnb precursora, de produzir uma molécula de ifnb glicosilada, para preparar uma variante conjugada e de tratar um mamìfero com esclerose múltiplam composição farmacêutica, molécula de ifnb variante, sequência de nucleotìdeo, vetor de expressão, célula hospedeira de glicosilação conjugado, e, uso de um conjugado
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CN105131104B (zh) 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
MXPA04010781A (es) 2002-04-30 2005-03-07 Maxygen Holdings Ltd Variantes de polipeptido del factor vii o viia.
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
AU2003303595A1 (en) 2002-12-30 2004-07-29 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
JP2007523630A (ja) 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド ヒト成長ホルモングリコシル化突然変異体の組成と調合法
GB0314472D0 (en) * 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
JP2007533298A (ja) 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Ｉｌ−２１の誘導体
ES2428358T3 (es) 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
AU2005238015A1 (en) * 2004-04-21 2005-11-10 Alza Corporation Polymer conjugate releasable under mild thiolytic conditions
KR20070027621A (ko) 2004-06-08 2007-03-09 알자 코포레이션 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
PL2586456T3 (pl) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling i glikopegilacja czynnika wzrostu fibroblastów (FGF)
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20100135959A1 (en) 2005-06-03 2010-06-03 Ambrx, Inc. Human Interferon Molecules and Their Uses
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP1937824B1 (en) 2005-08-18 2013-03-13 Ambrx, Inc. COMPOSITIONS OF tRNA AND USES THEREOF
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP1797901A1 (en) 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
AU2007227641B2 (en) 2006-03-13 2012-11-29 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
BRPI0712008A2 (pt) 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag derivados e análogos de fix prolongados
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2061878B1 (en) 2006-09-08 2014-01-08 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
MX2009003470A (es) 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
BRPI0809670A8 (pt) 2007-04-03 2018-12-18 Biogenerix Ag métodos para aumentar a produção de célula tronco, para aumentar o número de granulócitos em um indivíduo, para prevenir, tratar e aliviar a mielossupressão que resulta de uma terapia contra o câncer, para tratar uma condição em um indivíduo, para tratar neutropenia e trombocitopenia em um mamífero, para expandir células tronco hematopoiéticas em cultura, para aumentar a hematopoiese em um indivíduo, para aumentar o número de célulars progenitoras hematopoiéticas em um indivíduo, e para fornecer enxerto estável da medula óssea, e, forma de dosagem oral.
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
ES2476690T3 (es) 2008-02-27 2014-07-15 Novo Nordisk A/S Moléculas conjugadas del Factor VIII
EP2300514B1 (en) * 2008-07-14 2016-03-23 Biocon Limited A method of synthesizing a substantially monodispersed mixture of oligomers
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
DK2342223T3 (da) 2008-09-26 2017-07-24 Ambrx Inc Modificerede dyre-erythropoietin-polypeptider og deres anvendelser
MX2011003196A (es) 2008-09-26 2011-04-27 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
DK2440239T3 (da) 2009-06-09 2017-10-16 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP3815708A1 (en) 2010-03-05 2021-05-05 Omeros Corporation Chimeric inhibitor molecules of complement activation
EP2569331A1 (en) 2010-05-10 2013-03-20 Perseid Therapeutics LLC Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
PH12013500241A1 (en) 2010-08-17 2013-03-11 Ambrx Inc Modified relaxin polypeptides and their uses
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
MX2013009862A (es) 2011-03-02 2013-10-25 Novo Nordisk As Factor de coagulacion dirigido al transcripto 1 tipo trem (tlt-1) en plaquetas activadas.
JP6166258B2 (ja) 2011-06-15 2017-07-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ブレビバクテリウム・オーランチアカム（Ｂｒｅｖｉｂａｃｔｅｒｉｕｍａｕｒａｎｔｉａｃｕｍ）から単離されたポリペプチド及び癌の治療を目的とするその使用
CN103930440A (zh) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 松弛素融合多肽及其用途
EP2717917B1 (en) 2011-07-05 2016-04-20 biOasis Technologies Inc P97-antibody conjugates
US9884094B2 (en) 2012-05-01 2018-02-06 Novo Nordisk A/S Method of treating diabetes mellitus
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
CA2880162C (en) 2012-07-31 2023-04-04 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
AU2013344464A1 (en) 2012-11-16 2015-05-21 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
ES2926773T3 (es) 2013-03-15 2022-10-28 Novo Nordisk As Anticuerpos capaces de unirse específicamente a dos epítopos en el inhibidor de la ruta del factor tisular
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
IL259186B2 (en) 2015-11-09 2023-03-01 Scherer Technologies Llc R P Anti-cd22-maytensin antibody conjugates and methods of using them
KR102836360B1 (ko) 2016-04-15 2025-07-23 베크만 컬터, 인코포레이티드 광활성 거대분자 및 그의 용도
HUE057856T2 (hu) 2016-06-01 2022-06-28 Servier Ip Uk Ltd Polialkilén-oxid-aszparagináz készítményei és eljárás ezek elõállítására és alkalmazására
EP3529615A1 (en) 2016-10-24 2019-08-28 Novo Nordisk A/S Bioassay for insulin formulations
CN119264699A (zh) 2016-12-12 2025-01-07 贝克顿·迪金森公司 水溶性聚合物染料
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019038420A1 (en) 2017-08-25 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
CN111094462A (zh) 2017-12-26 2020-05-01 贝克顿·迪金森公司 深紫外线可激发的水溶剂化聚合物染料
US10844228B2 (en) 2018-03-30 2020-11-24 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
EP3849614B1 (en) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
WO2021048171A1 (en) 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of using them
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
MX2023007767A (es) 2020-12-28 2023-07-07 Davol Inc Materiales hemostaticos secos en polvo reactivos que comprenden una proteina y un agente de entrelazado a base de polietilenglicol modificado multifuncional.
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022200469A1 (en) 2021-03-24 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) A dominant negative protein of rad51 for treating cancer
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
CN114965761B (zh) * 2022-05-17 2024-07-02 深圳赛保尔生物药业有限公司 聚乙二醇化蛋白药物中n-羟基琥珀酰亚胺的检测方法
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
EP4680677A1 (en) 2023-03-17 2026-01-21 Beckman Coulter, Inc. Benzothienopyrrole cyanine dyes
WO2025045915A1 (en) 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025064842A1 (en) 2023-09-21 2025-03-27 Beckman Coulter, Inc. Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025215206A1 (en) 2024-04-12 2025-10-16 Institut National de la Santé et de la Recherche Médicale Activator of primary cilia to treat cognitive dysfunctions or ciliopathies
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631656C2 (de) * 1976-07-14 1983-02-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung eines Hydroxysuccinimidoester-Derivats zur Bindung von biologisch aktiven Proteinen aneinander und/oder an flüssige oder feste Trägerstoffe
CS204190B1 (en) † 1978-02-22 1981-03-31 Jaroslav Drobnik Activation method for hydrxyl groups containing insoluble carriers
YU144584A (en) † 1983-08-25 1987-06-30 Akad Wissenschaften Ddr Process for making n-(chlorocarbonyloxi)-s-norbornen-2,3-dicarboximide
DD219490A1 (de) † 1983-10-28 1985-03-06 Akad Wissenschaften Ddr Verfahren zur herstellung aktivierter traeger
JPS60156395A (ja) * 1984-01-17 1985-08-16 Mihama Hisaharu 修飾リパーゼ
DE3413904A1 (de) * 1984-04-13 1985-10-24 Hoechst Ag, 6230 Frankfurt Polymerisate auf basis von polyvinylencarbonat und/oder polyhydroxymethylen, verfahren zu ihrer herstellung und ihre anwendung
FR2574075B1 (fr) 1984-12-04 1987-09-18 Poudres & Explosifs Ste Nale Procede de synthese d'esters actifs d'acides carboxyliques, nouveaux carbonates alpha-halogenes utiles pour cette synthese et leur mode d'obtention
JPH0757760B2 (ja) * 1987-06-05 1995-06-21 宇部興産株式会社 生体由来物質の固定化方法
DD261791A1 (de) † 1987-06-30 1988-11-09 Akad Wissenschaften Ddr Verfahren zur herstellung von carbonaten hydroxylgruppenhaltiger polymere
DD260701A1 (de) † 1987-06-30 1988-10-05 Akad Wissenschaften Ddr Verfahren zur umesterung von aktiven unsymmetrischen kohlensaeurediester-gruppen an hydroxylgruppenhaltigen polymeren
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US4847325A (en) † 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides

Also Published As

Publication number Publication date
EP0893439A1 (en) 1999-01-27
ATE300519T1 (de) 2005-08-15
DE69034200T2 (de) 2006-05-24
EP0893439B1 (en) 2005-07-27
JP2875884B2 (ja) 1999-03-31
DK0470128T3 (da) 2000-01-10
ATE181732T1 (de) 1999-07-15
DE69033192T2 (de) 2000-03-09
DE69034200D1 (de) 2005-09-01
EP0470128A1 (en) 1992-02-12
ES2247656T3 (es) 2006-03-01
WO1990013540A1 (en) 1990-11-15
CA2053317C (en) 1996-03-12
JPH04504872A (ja) 1992-08-27
EP0470128A4 (en) 1992-09-16
ES2136595T3 (es) 1999-12-01
EP0470128B1 (en) 1999-06-30
DK0893439T3 (da) 2005-09-05
DE69033192D1 (de) 1999-08-05
DE69033192T3 (de) 2004-05-19
AU5526690A (en) 1990-11-29
HU903628D0 (en) 1991-12-30
HUT64022A (en) 1993-11-29
EP0470128B2 (en) 2003-08-13
CA2053317A1 (en) 1990-10-20
ES2136595T5 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
DK0470128T4 (da) Aktive polyalkylenoxidcarbonater til modifikation af polypeptider
ATE424431T2 (de) Verfahren zur herstellung von 1- benzotriazolcarbonatestern von wasserlöslichen polymeren
DK0682944T3 (da) Stabil, lyofiliseret, proteinholdig formulering og doseringskit
DE69942231D1 (de) Ortspezifische duale pegylation von proteine
ZA958892B (en) Injection-molded dosage form
NO990560L (no) Kjemisk modifiserte polypeptider
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
AU7761594A (en) Polyethylene glycols
RU2002120486A (ru) Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов
DE68925773D1 (de) Osteogene vorrichtungen
FR2681326B1 (fr) Nouveaux derives peptidiques, leur preparation et leur utilisation comme medicaments.
DK0402300T3 (da) Fremstilling i bakterier af gær og hæmoglobin og analoger dertil
ES2300276T3 (es) P40 de interleuquina-12 de mamifero e interleuquina b30. sus combinaciones. anticuerpos. usos en composiciones farmaceuticas.
FI913476A7 (fi) Konjugaattirokotteita, jotka sisältävät immunogeenista proteiinia, HIV-tyyppisiä peptidejä ja anionisia ryhmiä
ES548421A0 (es) Un procedimiento para la obtencion de un anticuerpo monoclo-nal
DE69636714D1 (de) G-CSF TPO Fusionsproteine
FI905825A0 (fi) Amfifiliska peptider och deras anvaendning.
SE8601563D0 (sv) Matrismaterial, forfarande for framstellning derav och anvendning derav
ES2144392T3 (es) Vectores de expresion para la sintesis de proteinas en la levadura de escision schizosaccharomyces pombe.
ATE135407T1 (de) Peptide, welche hiv-retroviren-hemmende antikörper induzieren, sowie gegen diese peptide gerichtete antikörper
DE50009177D1 (de) Proteinhaltige Hydrogele
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
KR950701347A (ko) 신규한 향종양성 사이토킨(A novel anti-neoplastic cytokine)
CA2088478A1 (en) Cloning and expression of a rhoptry associated protein of p. falciparum
FR2661188B1 (fr) Nouveaux vecteurs de clonage et/ou d'expression, procede de preparation et leur utilisation.